What's new

Human medicines European public assessment report (EPAR): Briumvi, ublituximab, Date of authorisation: 31/05/2023, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Briumvi, ublituximab, Date of authorisation: 31/05/2023, Revision: 6, Status: Authorised

May 6, 2025 - 15:41
 0
Human medicines European public assessment report (EPAR): Briumvi, ublituximab, Date of authorisation: 31/05/2023, Revision: 6, Status: Authorised
Human medicines European public assessment report (EPAR): Briumvi, ublituximab, Date of authorisation: 31/05/2023, Revision: 6, Status: Authorised
Read More

Tags:

Previous Article

'Now is not the time to retreat': BMS CEO blasts Trump admin tariffs, health ref...

Next Article

Human medicines European public assessment report (EPAR): Zolgensma, onasemnogen...

Related Posts

EMA Agile governance model

Apr 30, 2025  0

Human medicines European public assessment report (EPAR): Bortezomib Sun, bortezomib, Date of authorisation: 22/07/2016, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR...

May 6, 2025  0

Business process description for scientific meeting man...

Apr 22, 2025  0